Greenwich

$31.83 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Greenwich

Greenwich LifeSciences, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.

Stock Analysis

last close $33.1
1-mo return -5.8%
3-mo return -17.9%
avg daily vol. 20.14T
52-week high 158.07
52-week low 5.01
market cap. $434M
forward pe -
annual div. -
roe -20.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 6.3%
baraka

Subscribe now for daily local and international financial news

Subscribe